Fluphenazine and Fluphenazine Decanoate

Jonathan M. Meyer; Stephen M. Stahl

doi:10.1017/9781009002103.011

8 - Fluphenazine and Fluphenazine Decanoate

Published online by Cambridge University Press: 19 October 2021

Jonathan M. Meyer and

Stephen M. Stahl

Show author details

Jonathan M. Meyer: Affiliation:
University of California, San Diego
Stephen M. Stahl: Affiliation:
University of California, Riverside and San Diego

Book contents

Get access

Summary

As with many first-generation antipsychotics (FGAs), fluphenazine has no unique therapeutic benefit compared to other D2 antagonists, but does have multiple formulations including a long-acting injectable (LAI), and an extensive database of plasma level information [1–2, 5–12]. The cytochrome P450 pathways and effects of inhibitors and inducers are less well studied than for other FGAs, and there are fewer studies on oral dose–concentration relationships which account for confounding issues such as smoking [3].

Type: Chapter
Information: The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 174 - 189

DOI: https://doi.org/10.1017/9781009002103.011 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Dysken, M. W., Javaid, J. I., Chang, S. S., et al. (1981). Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology (Berl), 73, 205–210.Google Scholar

Levinson, D. F., Simpson, G. M., Lo, E. S., et al. (1995). Fluphenazine plasma levels, dosage, efficacy, and side effects. Am J Psychiatry, 152, 765–771.Google Scholar

Ereshefsky, L., Jann, M. W., Saklad, S. R., et al. (1985). Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry, 20, 329–332.Google Scholar

Koreen, A. R., Lieberman, J., Alvir, J., et al. (1994). Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients. Am J Psychiatry, 151, 35–39.Google Scholar

Marder, S. R., Midha, K. K., Van Putten, T., et al. (1991). Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: Relationship to clinical response. Br J Psychiatry, 158, 658–665.Google Scholar

Midha, K. K., Hubbard, J. W., Marder, S. R., et al. (1994). Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci, 19, 254–264.Google Scholar

Jann, M. W., Ereshefsky, L., and Saklad, S. R. (1985). Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet, 10, 315–333.Google Scholar

Marder, S. R., Van Putten, T., Aravagiri, M., et al. (1989). Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine. Psychopharmacol Bull, 25, 479–482.Google Scholar

Van Putten, T., Marder, S. R., Wirshing, W. C., et al. (1991). Neuroleptic plasma levels. Schizophr Bull, 17, 197–216.Google Scholar

Miller, R. S., Peterson, G. M., McLean, S., et al. (1995). Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate. J Clin Pharm Ther, 20, 55–62.Google Scholar

Gitlin, M. J., Nuechterlein, K. H., Mintz, J., et al. (2000). Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: Relation to side effects, psychosocial function and depression. Psychopharmacology, 148, 350–354.Google Scholar

Marder, S. R., Aravagiri, M., Wirshing, W. C., et al. (2002). Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. Schizophr Res, 53, 25–30.Google Scholar

Van Putten, T., Aravagiri, M., Marder, S. R., et al. (1991). Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients. Psychopharmacol Bull, 27, 91–96.Google Scholar

Coppens, H. J., Slooff, C. J., Paans, A. M., et al. (1991). High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol Psychiatry, 29, 629–634.Google Scholar

Nyberg, S., Dencker, S. J., Malm, U., et al. (1998). D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients. Int J Neuropsychopharmacol, 1, 95–101.Google Scholar

Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: A joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi/10.4088/JCP.4019cs13169.Google Scholar

Midha, K. K., Hawes, E. M., Hubbard, J. W., et al. (1988). Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients. Psychopharmacology (Berl), 96, 206–211.Google Scholar

Koytchev, R., Alken, R. G., McKay, G., et al. (1996). Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. Eur J Clin Pharmacol, 51, 183–187.Google Scholar

Aravagiri, M., Marder, S. R., Yuwiler, A., et al. (1995). Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat. Neuropsychopharmacology, 13, 235–247.Google Scholar

Goff, D. C., Midha, K. K., Sarid-Segal, O., et al. (1995). A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl), 117, 417–423.Google Scholar

Jann, M. W., Fidone, G. S., Hernandez, J. M., et al. (1989). Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation. Psychiatry Res, 28, 153–159.Google Scholar

Coffman, J. A., Nasrallah, H. A., Lyskowski, J., et al. (1987). Clinical effectiveness of oral and parenteral rapid neuroleptization. J Clin Psychiatry, 48, 20–24.Google Scholar

Harasko-van der Meer, C., Brucke, T., Wenger, S., et al. (1993). Two cases of long term dopamine D2 receptor blockade after depot neuroleptics. J Neural Transm, 94, 217–221.Google Scholar

Carpenter, W. T., Jr., Buchanan, R. W., Kirkpatrick, B., et al. (1999). Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiatry, 156, 412–418.Google Scholar

Taylor, D. (2009). Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review. Br J Psychiatry Suppl, 52, S13–19.Google Scholar

Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R. and Knollmann, B. C., eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th edn. Chicago, IL: McGraw-Hill, pp. 279–302.Google Scholar

Ereshefsky, L., Saklad, S. R., Jann, M. W., et al. (1984). Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry, 45, 50–59.Google Scholar

Bristol-Myers Squibb Company (2017). Modecate Concentrate (Fluphenazine Decanoate injection, BP 100 mg/ml) product monograph. Montreal, Canada.Google Scholar

Haddad, P., Lambert, T., and Lauriello, J., eds. (2016). Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press.Google Scholar

Ereshefsky, L. and Mascarenas, C. A. (2003). Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry, 64, 18–23.Google Scholar

Meyer, J. M. (2017). Converting oral to long acting injectable antipsychotics: A guide for the perplexed. CNS Spectr, 22, 14–28.Google Scholar

Glazer, W. M. (1988). Fluphenazine decanoate: Its steady-state pharmacologic profile and relationship to tardive dyskinesia. Schizophr Res, 1, 425–429.Google Scholar

Heresco-Levy, U., Greenberg, D., Lerer, B., et al. (1997). Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy. Isr J Psychiatry Relat Sci, 34, 281–289.Google Scholar

Baldelli, S., Clementi, E., and Cattaneo, D. (2018). Can we rely on AGNP therapeutic targets also for LAI antipsychotics? Pharmacopsychiatry, 51, 270–271.Google Scholar

Uchida, H., Takeuchi, H., Graff-Guerrero, A., et al. (2011). Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: A systematic review and pooled analysis. J Clin Psychopharmacol, 31, 318–325.Google Scholar

Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: Case vignettes. CNS Spectr, 19, 432–438.Google Scholar

Meyer, J. M. (2020). Monitoring and improving antipsychotic adherence in outpatient forensic diversion programs. CNS Spectr, 25, 136–144.Google Scholar

Simpson, G. M. and Kunz-Bartholini, E. (1968). Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis Nerv System, 29, 269–274.Google Scholar

Kane, J., Honigfeld, G., Singer, J., et al. (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 45, 789–796.Google Scholar

Kapur, S. and Seeman, P. (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry, 158, 360–369.Google Scholar

Sparshatt, A., Taylor, D., Patel, M. X., et al. (2010). A systematic review of aripiprazole – dose, plasma concentration, receptor occupancy, and response: Implications for therapeutic drug monitoring. J Clin Psychiatry, 71, 1447–1556.Google Scholar

Seneca, N., Finnema, S. J., Laszlovszky, I., et al. (2011). Occupancy of dopamine D(2) and D(3) and serotonin 5-HT(1)A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl), 218, 579–587.Google Scholar

Uchida, H., Takeuchi, H., Graff-Guerrero, A., et al. (2011). Dopamine D2 receptor occupancy and clinical effects: A systematic review and pooled analysis. J Clin Psychopharmacol, 31, 497–502.Google Scholar

Lim, H. S., Kim, S. J., Noh, Y. H., et al. (2013). Exploration of optimal dosing regimens of haloperidol, a D2 antagonist, via modeling and simulation analysis in a D2 receptor occupancy study. Pharm Res, 30, 683–693.Google Scholar